Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors

NCT04669899 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

190

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: JTX-8064
DRUG: pimivalimab

Sponsor

Jounce Therapeutics, Inc.